Plain-English translation of NCT05376878 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a new type of imaging scan called 64Cu-DOTA- PET/MRI in women with HER2-positive breast cancer that has spread to the brain. The scan uses a special marker attached to an antibody to help doctors see cancer cells more clearly. Researchers want to find out if this imaging can predict which patients will respond well to a targeted cancer medication called fam-.
Currently, doctors don't have a reliable way to predict whether patients will respond to treatment for brain metastases from breast cancer. This new imaging technique may help doctors understand how well the medication is working earlier, so they can adjust treatment plans faster if needed.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of on day 1, followed by the special imaging agent and a PET/MRI scan on day 2. Then you would have brain MRI scans every 6 weeks for 6 months, and then every 9 weeks after that to monitor your cancer. Throughout the study, you would also receive the cancer medication fam- by IV infusion every 3 weeks. The study team will follow you until your cancer starts growing again or you experience unacceptable side effects.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
United States